Clinical Trials Browser

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Completed

514 enrolled

LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT02690545 2026-01-06

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Phase 1/2 Active not recruiting

38 enrolled

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT03602157 2026-01-06

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Phase 1 Active not recruiting

43 enrolled

DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Phase 1 Active not recruiting

19 enrolled

Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Phase 1/2 Active not recruiting

17 enrolled

LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02663297 2025-05-15

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Phase 1 Active not recruiting

18 enrolled 10 charts

Lymphoid

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT06644443 2024-10-16

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

10 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04097067 2024-08-27

ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

Phase NA Recruiting

83 enrolled

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02670564 2019-04-16

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

Phase 4 Unknown

1,000 enrolled

LymphoidOther hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02366663 2018-03-12

SPINOZA

Phase 3 Terminated

3 enrolled 8 charts

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03373019 2017-12-14

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Unknown

63 enrolled

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00701844 2017-11-17

Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors

Phase NA Completed

315 enrolled

Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Anemia, Aplastic, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

SPiReL

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

SPINOZA

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors